{
  "docId": "019dd923-622c-750b-8b97-e9d223c0ba42",
  "docSlug": "88a4417a0cf1",
  "documentTitle": "Apellis Pharmaceuticals (APLS)",
  "authorId": "52_Citron_Research",
  "authorName": "Citron Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-11-06 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77295077,
  "pageNumber": 1,
  "pageCount": 13,
  "prevPage": null,
  "nextPage": 2,
  "slideType": "executive_summary",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Includes a testimonial/marketing image from Apellis featuring Henry Winkler.",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "paragraph",
    "photo",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": "https://imgproxy.kitesheet.com/Mmja_6VvazvEnEMQ9QArk9HtH-S_v08L9yygDCJhINk/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84OGE0NDE3YTBjZjEvcDAwMS5wbmc",
  "slideHref": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/1",
  "deckHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-1",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Happy Days Are OVER for Apellis, as the Experts Give a Thumbs Down to Syfovre. Citron Expects FDA Warning Letter.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-1ac1-76e9-bcd4-cc93d867a503",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.3,
        "y": 0.48
      },
      "kind": "image",
      "text": "Henry Winkler advertisement for Apellis",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f04a09ad-331a-4883-88dd-19dcf507f281",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.11,
        "y": 0.67
      },
      "kind": "paragraph",
      "text": "Four months after releasing Syfovre, the drama began. Apellis Pharmaceuticals was hit with reports from the ASRS of retinal vasculitis as a side effect, causing their stock to drop.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35714d86-078c-4f9d-9a44-c8c2663fde4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Citron Research was committed to ensuring that its return to short selling was marked by a report that would not only hinge on valuation concerns but also spotlight a company whose activities could be detrimental to the public interest.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d5c8c6a-f43c-4ff7-9c80-948f124bbb4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "The following month Favus Research initiated a report claiming the Apellis trials didn't sufficiently report 14 cases of retinal vasculitis, an inflammatory condition that kills blood vessels in patients receiving the therapy.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b54dbe4-e8a2-414a-aee0-d8c3b8df06b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"If I started seeing changes, I'd carry my car to the eye doctor's office. That's how on top of your vision you have to be.\" — Henry Winkler",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-1ac1-76e9-bcd4-d0d1decb7a84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.11,
        "y": 0.15
      },
      "kind": "title",
      "text": "Happy Days Are OVER for Apellis, as the Experts Give a Thumbs Down to Syfovre. Citron Expects FDA Warning Letter.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfc82f20-2231-439a-b8b7-f39dfa6d737e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.11,
        "y": 0.11
      },
      "kind": "title",
      "text": "Citron Research Reports on Apellis Pharmaceuticals (APLS)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b32f4af9-2502-48c5-b525-f1cabd3a009d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 13,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac",
      "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.",
      "position": 1,
      "objective": "What are the consequences of not taking action against Syfovre's safety concerns?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": "https://imgproxy.kitesheet.com/rXUOR0OVxFKl-V28oNxbX2At6IOUdHtI7IYe5ndnKwk/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84OGE0NDE3YTBjZjEvcDAwMS5qcGc",
  "thumbSrc": "https://imgproxy.kitesheet.com/wsXpOoTN90w7OABeUlU1gF3p7I0wSwwGrsj704WFn2w/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84OGE0NDE3YTBjZjEvcDAwMS5wbmc",
  "thumbSrcAlt": "https://imgproxy.kitesheet.com/lf3end9R1s47ivHhi9695o9NX5gHpEhH4g6j0HXtBDg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84OGE0NDE3YTBjZjEvcDAwMS5qcGc"
}